Targeting the BH3-interacting domain death agonist to develop mechanistically unique antidepressants

Molecular Psychiatry

Volumn 17, Issue 8, 2012, Pages 770-780

  Malkesman, O ^a   Austin, D R ^a   Tragon, T ^a   Henter, I D ^a   Reed, J C ^b   Pellecchia, M ^b   Chen, G ^a,c   Manji, H K ^a,c  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b BURNHAM INSTITUTE   (United States)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

AIF; Bcl 2; behavior; Bid; depression; stress

Indexed keywords

APOPTOSIS INDUCING FACTOR; BI 11A7; BI 2A7; CASPASE; CITALOPRAM; PROTEIN BCL 2; PROTEIN BID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; CELL DEATH; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DEPRESSION; EXPERIMENTAL MODEL; FEMALE URINE SNIFFING TEST; FORCED SWIM TEST; IMMOBILIZATION; LEARNED HELPLESSNESS; MALE; MOOD DISORDER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REWARD; RODENT; TAIL SUSPENSION TEST;

ANILINE COMPOUNDS; ANIMALS; ANTIDEPRESSIVE AGENTS; APOPTOSIS INDUCING FACTOR; BEHAVIOR, ANIMAL; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CARRIER PROTEINS; CITALOPRAM; CYTOCHROMES C; DEPRESSION; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; INFUSIONS, INTRAVENTRICULAR; MALE; MICE; MICE, INBRED STRAINS; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; SULFIDES; SULFONAMIDES;

EID: 84864376897     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2011.77     Document Type: Article

References (72)

1. Duman RS. Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: stress and depression. Dialog Clin Neurosci 2009; 11: 239-255.
2. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med 2008; 358: 55-68.
3. Hunsberger J, Austin DR, Henter ID, Chen G. The neurotrophic and neuroprotective effects of psychotropic agents. Dialog Clin Neurosci 2009; 11: 333-348.
4. Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med 2001; 7: 541-547. (Pubitemid 32448319)
5. Goldman LS, Nielsen NH, Champion HC. Awareness, diagnosis, and treatment of depression. J Gen Intern Med 1999; 14: 569-580. (Pubitemid 29441639)
6. Simon GE. Social and economic burden of mood disorders. Biol Psychiatry 2003; 54: 208-215. (Pubitemid 37267852)
7. World Health Organization. The Global Burden of Disease (GBD) 2004. Update. 2008 (cited 1 October 2009); available from: http://www.who.int/ healthinfo/global-burden-disease/2004-report-update/en/index.html.
8. Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002; 68: 167-181. (Pubitemid 34628324)
9. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry 1998; 173: 11-53. (Pubitemid 28312203)
10. Hiroeh U, Appleby L, Mortensen PB, Dunn G. Death by homicide, suicide, and other unnatural causes in people with mental illness: a population-based study. Lancet 2001; 358: 2110-2112. (Pubitemid 34094900)
11. Goodwin FK, Jamison KR. Manic-Depressive Illness: Bipolar and Recurrent Unipolar Disorders, 2nd edn. Oxford University Press: New York, 2007.
12. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 2008; 455: 894-902.
13. Coyle JT, Duman RS. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 2003; 38: 157-160. (Pubitemid 36555643)
14. Manji HK, Quiroz JA, Sporn J, Payne JL, Denicoff K, A Gray N et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 2003; 53: 707-742. (Pubitemid 39658487)
15. Hunsberger JG, Austin DR, Chen G, Manji HK. Cellular mechanisms underlying affective resiliency: the role of glucocorticoid receptor-and mitochondrially-mediated plasticity. Brain Res 2009; 1293: 76-84.
16. Hunsberger JG, Austin DR, Chen G, Manji HK. MicroRNAs in mental health: from biological underpinnings to potential therapies. Neuromol Med 2009; 11: 173-182.
17. Reed JC. Apoptosis mechanisms: implications for cancer drug discovery. Oncology (Williston Park) 2004; 13(Suppl 10): 11-20.
18. Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene 2008; 27: 6398-6406.
19. Hetz C, Glimcher L. The daily job of night killers: alternative roles of the BCL-2 family in organelle physiology. Trends Cell Biol 2008; 18: 38-44.
20. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
21. Kuhn HG, Biebl M, Wilhelm D, Li M, Friedlander RM, Winkler J. Increased generation of granule cells in adult BCL-2-overexpressing mice: a role for cell death during continued hippocampal neurogenesis. Eur J Neurosci 2005; 22: 1907-1915. (Pubitemid 41579381)
22. Chen G, Ray R, Dubik D, Shi L, Cizeau J, Bleackley RC et al. The E1B 19K/BCL-2-binding protein Nip3 is a dimeric mitochondrial protein that activates apoptosis. J Exp Med 1997; 186: 1975-1983. (Pubitemid 28013681)
23. Hao Y, Creson T, Zhang L, Li P, Du F, Yuan P et al. Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J Neurosci 2004; 24: 6590-6599. (Pubitemid 38971708)
24. Yuan P, Huang LD, Jiang YM, Gutkind JS, Manji HK, Chen G. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem 2001; 276: 31674-31683.
25. Jonas E. BCL-xL regulates synaptic plasticity. Mol Interv 2006; 6: 208-222. (Pubitemid 44455203)
26. Mattson MP. Mitochondrial regulation of neuronal plasticity. Neurochem Res 2007; 32: 707-715. (Pubitemid 46481300)
27. Kosten TA, Galloway MP, Duman RS, Russell DS, D'Sa C. Repeated unpredictable stress and antidepressants differentially regulate expression of the BCL-2 family of apoptotic genes in rat cortical, hippocampal, and limbic brain structures. Neuropsychopharmacology 2007; 33: 1545-1558. (Pubitemid 351684697)
28. Huang YY, Peng CH, Yang YP, Wu CC, Hsu WM, Wang HJ et al. Desipramine activated BCL-2 expression and inhibited lipopolysaccharide-induced apoptosis in hippocampus-derived adult neural stem cells. J Pharmacol Sci 2007; 104: 61-72.
29. Murray F, Hutson PH. Hippocampal BCL-2 expression is selectively increased following chronic but not acute treatment with antidepressants, 5-HT(1A) or 5-HT(2C/2B) receptor antagonists. Eur J Pharmacol 2007; 13: 41-47. (Pubitemid 47175878)
30. Xu H, Richardson J, Li XM. Dose-related effects of chronic antidepressants on neuroprotective proteins BDNF, BCL-2 and Cu/Zn-SOD in rat hippocampus. Neuropsychopharmacology 2003; 28: 53-62.
31. Bravo JA, Diaz-Veliz G, Mora S, Ulloa JL, Berthoud VM, Morales P et al. Desipramine prevents stress-induced changes in depressivelike behavior and hippocampal markers of neuroprotection. Behav Pharmacol 2009; 20: 273-285.
32. Maeng S, Hunsberger JG, Pearson B, Yuan P, Wang Y, Wei Y et al. BAG1 plays a critical role in regulating recovery from both maniclike and depression-like behavioral impairments. Proc Natl Acad Sci USA 2008; 105: 8766-8771. (Pubitemid 351987754)
33. Schendel SL, Azimov R, Pawlowski K, Godzik A, Kagan BL, Reed JC. Ion channel activity of the BH3 only BCL-2 family member, BID. J Biol Chem 1999; 274: 21932-21936.
34. Breckenridge DG, Stojanovic M, Marcellus RC, Shore GC. Caspase cleavage product of BAP31 induces mitochondrial fission through endoplasmic reticulum calcium signals, enhancing cytochrome c release to the cytosol. J Cell Biol 2003; 160: 1115-1127. (Pubitemid 36443879)
35. Cregan SP, Dawson VL, Slack RS. Role of AIF in caspasedependent and caspase-independent cell death. Oncogene 2004; 23: 2785-2796. (Pubitemid 38638842)
36. Yin XM, Wang K, Gross A, Zhao Y, Zinkel S, Klocke B et al. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 1999; 400: 886-891. (Pubitemid 29406726)
37. Zou H, Li Y, Liu X, Wang X. An APAF-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 1999; 274: 11549-11556.
38. Plesnila N, Zinkel S, Le DA, Amin-Hanjani S, Wu Y, Qiu J et al. BID mediates neuronal cell death after oxygen/glucose deprivation and focal cerebral ischemia. Proc Natl Acad Sci USA 2001; 98: 15318-15323. (Pubitemid 34014012)
39. Culmsee C, Zhu C, Landshamer S, Becattini B, Wagner E, Pellecchia M et al. Apoptosis-inducing factor triggered by poly(ADP-ribose) polymerase and Bid mediates neuronal cell death after oxygen-glucose deprivation and focal cerebral ischemia. J Neurosci 2005; 25: 10262-10272. (Pubitemid 41636223)
40. Cregan SP, Fortin A, MacLaurin JG, Callaghan SM, Cecconi F, Yu SW et al. Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death. J Cell Biol 2002; 158: 507-517. (Pubitemid 34851709)
41. Becattini B, Culmsee C, Leone M, Zhai D, Zhang X, Crowell KJ et al. Structure-activity relationships by interligand NOE-based design and synthesis of antiapoptotic compounds targeting Bid. Proc Natl Acad Sci USA 2006; 103: 12602-12606. (Pubitemid 44267305)
42. Becattini B, Sareth S, Zhai D, Crowell KJ, Leone M, Reed JC et al. Targeting apoptosis via chemical design: inhibition of bid-induced cell death by small organic molecules. Chem Biol 2004; 11: 1107-1117. (Pubitemid 39138763)
43. Thakker DR, Natt F, Husken D, van der Putten H, Maier R, Hoyer D et al. siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain. Mol Psychiatry 2005; 10: 782-789. (Pubitemid 41129051)
44. Xu B, Pu S, Kalra PS, Hyde JF, Crowley WR, Kalra SP. An interactive physiological role of neuropeptide Y and galanin in pulsatile pituitary luteinizing hormone secretion. Endocrinology 1996; 137: 5297-5302. (Pubitemid 26423088)
45. Shaltiel G, Maeng S, Malkesman O, Pearson B, Schloesser RJ, Tragon T et al. Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania. Mol Psychiatry 2008; 13: 858-872.
46. Gould TD, O'Donnell KC, Dow ER, Du J, Chen G, Manji HK. Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test. Neuropharmacology 2008; 54: 577-587.
47. Maeng S, Zarate Jr CA, Du J, Schloesser RJ, McCammon J, Chen G et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008; 63: 349-352. (Pubitemid 351146651)
48. Malkesman O, Scattoni ML, Paredes D, Tragon T, Pearson B, Shaltiel G et al. The female urine sniffing test: a novel approach for assessing reward-seeking behavior in rodents. Biol Psychiatry 2010; 67: 864-871.
49. Malkesman O, Austin DR, Chen G, Manji HK. Reverse translational strategies for developing animal models of bipolar disorder. Dis Model Mech 2009; 2: 238-245.
50. Cryan JF, Mombereau C. In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice. Mol Psychiatry 2004; 9: 326-357. (Pubitemid 38534696)
51. Cryan JF, Mombereau C, Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 2005; 29: 571-625. (Pubitemid 40755457)
52. Cryan JF, Markou A, Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002; 23: 238-245. (Pubitemid 34465544)
53. Engin E, Treit D, Dickson CT. Anxiolytic-and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models. Neuroscience 2009; 161: 359-369.
54. Foreman MM, Hanania T, Stratton SC, Wilcox KS, White HS, Stables JP et al. In vivo pharmacological effects of JZP-4, a novel anticonvulsant, in models for anticonvulsant, antimania and antidepressant activity. Pharmacol Biochem Behav 2008; 89: 523-534.
55. Liu X, Peprah D, Gershenfeld HK. Tail-suspension induced hyperthermia: a new measure of stress reactivity. J Psychiatr Res 2003; 37: 249-259. (Pubitemid 36313274)
56. Lucki I, Dalvi A, Mayorga AJ. Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology (Berl) 2001; 155: 315-322. (Pubitemid 32477289)
57. Abel EL. Ontogeny of immobility and response to alarm substance in the forced swim test. Physiol Behav 1993; 54: 713-716. (Pubitemid 23275754)
58. Mayorga AJ, Lucki I. Limitations on the use of the C57BL/6 mouse in the tail suspension test. Psychopharmacology (Berl) 2001; 155: 110-112. (Pubitemid 32295777)
59. Mombereau C, Kaupmann K, FroestlW, Sansig G, van der Putten H, Cryan JF. Genetic and pharmacological evidence of a role for GABA(B) receptors in the modulation of anxiety-and antidepressant-like behavior. Neuropsychopharmacology 2004; 29: 1050-1062. (Pubitemid 38670043)
60. Porsolt R, Lenegre A. Behavioral models of depresion. In: Elliot J, Heal D, Marsden C (eds). Experimental Approaches to Anxiety and Depression. Wiley and Sons: London, 1992, pp 73-85.
61. Chourbaji S, Zacher C, Sanchis-Segura C, Dormann C, Vollmayr B, Gass P. Learned helplessness: validity and reliability of depressive-like states in mice. Brain Res Brain Res Protoc 2005; 16: 70-78. (Pubitemid 41774074)
62. Henn FA, Edwards E, Muneyyirci. Animal models of depression. Clin Neurosci 1993; 1: 152-156.
63. Gambarana C, Scheggi S, Tagliamonte A, Tolu P, DeMontis MG. Animal models for the study of antidepressant activity. Brain Res Brain Res Protoc 2001; 7: 11-20. (Pubitemid 32241223)
64. Henkel V, Bussfeld P, Moller HJ, Hegerl U. Cognitive-behavioural theories of helplessness/hopelessness: valid models of depression? Eur Arch Psychiatry Clin Neurosci 2002; 252: 240-249. (Pubitemid 36068387)
65. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition (DSM-IV). American Psychiatric Association: Washington, DC, 2000.
66. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M et al. mTORdependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010; 329: 959-964.
67. Maier SF. Learned helplessness and animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry 1984; 8: 435-446. (Pubitemid 14051222)
68. Plesnila N, Zhu C, Culmsee C, Groger M, Moskowitz MA, Blomgren K. Nuclear translocation of apoptosis-inducing factor after focal cerebral ischemia. J Cereb Blood Flow Metab 2004; 24: 458-466. (Pubitemid 38452237)
69. Cheung EC, Melanson-Drapeau L, Cregan SP, Vanderluit JL, Ferguson KL, McIntosh WC et al. Apoptosis-inducing factor is a key factor in neuronal cell death propagated by BAX-dependent and BAX-independent mechanisms. J Neurosci 2005; 25: 1324-1334. (Pubitemid 40250708)
70. Landshamer S, Hoehn M, Barth N, Duvezin-Caubet S, Schwake G, Tobaben S et al. Bid-induced release of AIF from mitochondria causes immediate neuronal cell death. Cell Death Differ 2008; 15: 1553-1563.
71. McKernan DP, Dinan TG, Cryan JF. 'Killing the Blues': a role for cellular suicide (apoptosis) in depression and the antidepressant response? Prog Neurobiol 2009; 88: 246-263.
72. Drzyzga LR, Marcinowska A, Obuchowicz E. Antiapoptotic and neurotrophic effects of antidepressants: a review of clinical and experimental studies. Brain Res Bull 2009; 79: 248-257.